1. Home
  2. LITE vs IKT Comparison

LITE vs IKT Comparison

Compare LITE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lumentum Holdings Inc.

LITE

Lumentum Holdings Inc.

N/A

Current Price

$862.03

Market Cap

24.1B

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.76

Market Cap

240.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LITE
IKT
Founded
2015
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.1B
240.1M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
LITE
IKT
Price
$862.03
$1.76
Analyst Decision
Buy
Strong Buy
Analyst Count
15
5
Target Price
$609.71
$5.00
AVG Volume (30 Days)
5.3M
1.2M
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
104.56
57.76
EPS
0.99
N/A
Revenue
$1,247,700,000.00
N/A
Revenue This Year
$79.03
N/A
Revenue Next Year
$63.02
$33.33
P/E Ratio
$823.90
N/A
Revenue Growth
24.57
N/A
52 Week Low
$49.13
$1.33
52 Week High
$836.91
$2.37

Technical Indicators

Market Signals
Indicator
LITE
IKT
Relative Strength Index (RSI) 62.86 52.25
Support Level $549.99 $1.77
Resistance Level N/A $1.88
Average True Range (ATR) 69.12 0.11
MACD 8.47 0.01
Stochastic Oscillator 90.86 75.76

Price Performance

Historical Comparison
LITE
IKT

About LITE Lumentum Holdings Inc.

Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: